Valuation: Rezolute, Inc.

Market Cap 543M 477M 439M 409M 772M 51.65B 787M 5.28B 2.05B 25.35B 2.04B 2B 88.23B P/E 2026 *
-7.43x
P/E 2027 * -8x
Enterprise Value 543M 477M 439M 409M 772M 51.65B 787M 5.28B 2.05B 25.35B 2.04B 2B 88.23B EV / Sales 2026 *
-
EV / Sales 2027 * 236x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute, Inc.

1 day-4.81%
1 week-1.59%
Current month-4.81%
1 month+37.12%
3 months+58.15%
6 months+128.64%
Current year+109.75%
1 week 4.86
Extreme 4.86
5.42
1 month 3.58
Extreme 3.58
5.42
Current year 1.87
Extreme 1.87
5.42
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
14.45
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 2013-01-29
Director of Finance/CFO 52 2024-01-22
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 2022-05-03
Director/Board Member 55 2019-11-19
Chairman 68 2019-02-09
Date Insider Type Main position Quantity % Market Cap.
03-29Buy

Chief Financial Officer

10,000 0.0115%
03-01Tax

Chief Technology Officer

11,439 0.0131%
03-01Tax

Chief Financial Officer

11,438 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
-4.81%-1.59%+11.99%+144.44% 543M
-2.19%-2.39%+68.92%+123.30% 57.65B
+0.55%+17.77%+80.01%+100.93% 55.14B
+0.93%+4.11%-12.64%-12.89% 23.53B
+0.36%+3.42%+9.61%+415.66% 23.11B
-1.93%+11.11%+34.89%-7.86% 18.14B
+0.28%+5.36%+36.88%-30.23% 16.84B
-0.83%+2.06%+23.70%+182.07% 13.68B
+0.14%+9.60%+33.31% - 12.97B
-4.20%+0.91%+71.37%+127.83% 12.38B
Average -1.17%+5.63%+35.81%+115.92% 23.4B
Weighted average by Cap. -0.68%+4.62%+47.91%+115.27%

Financials

2026 *2027 *
Net sales - 2.3M 2.02M 1.86M 1.74M 3.27M 219M 3.34M 22.4M 8.68M 108M 8.65M 8.46M 374M
Net income -72.7M -63.83M -58.75M -54.75M -103M -6.91B -105M -707M -274M -3.39B -273M -267M -11.81B -75.12M -65.95M -60.71M -56.57M -107M -7.14B -109M -730M -283M -3.51B -282M -276M -12.2B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
26-07-01 US$4.950 -4.81% 2,427,629
26-06-30 US$5.200 +1.96% 3,368,014
26-06-29 US$5.100 +1.19% 1,753,923
26-06-26 US$5.040 +0.20% 6,577,310
26-06-25 US$5.030 0.00% 1,262,200
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.200USD
Average target price
7.667USD
Spread / Average Target
+47.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock